Respiratory investigation最新文献

{"title":"A refined approach to chest tube removal: Impact of preoperative pleural fluid culture and nutritional status in non-fistulous empyema surgery","authors":"Yasoo Sugiura ,&nbsp;Toshinori Hashizume ,&nbsp;Hiroyuki Fujimoto ,&nbsp;Seiji Omura ,&nbsp;Nozomi Watanobe","doi":"10.1016/j.resinv.2025.01.004","DOIUrl":"10.1016/j.resinv.2025.01.004","url":null,"abstract":"<div><h3>Background</h3><div>The acute pleural empyema guidelines recommend thoracoscopic-assisted surgery. However, there is no clear guideline for chest tube removal after surgery. This study aimed to evaluate the duration from surgery to chest tube removal, identify associated factors.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted in 95 patients having non-fistulous empyema due to pulmonary infection caused by common bacteria who underwent surgery at our hospital from January 2011 to March 2023. Postoperative lavage was conducted until two consecutive pleural fluid cultures were negative. The chest tube was clamped and removed if there was no exacerbation of fever or inflammatory findings for 2 days.</div></div><div><h3>Results</h3><div>Seventy-eight patients (82.1%) were men with a mean age of 72 years. The median duration from surgery to chest tube removal was 14 (interquartile range: 8–22) days. In the multivariable analysis, the independent factors associated with the duration from surgery to chest tube removal were lower prognostic nutritional index (hazard ratio [HR], 1.753; 95% confidence interval [CI], 1.101–2.792; P = 0.018) and positive preoperative pleural fluid culture (HR, 1.867; 95% CI, 1.069–3.261; P = 0.028). Ninety-two (96.8%) patients did not require additional treatment or rehospitalization.</div></div><div><h3>Conclusions</h3><div>Positive preoperative pleural fluid culture and nutritional status were significant independent factors associated with the duration from surgery to chest tube removal. Almost all patients did not require chest tube reinsertion in our approach. These findings using our approach may guide optimal management of chest tube removal in non-fistulous empyema.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 226-232"},"PeriodicalIF":2.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143222485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis” [Respir Invest Volume 62 (2024) 1079-1087]","authors":"Natsuki Nakagawa ,&nbsp;Masashi Ito ,&nbsp;Takanori Asakura ,&nbsp;Nobuyuki Horita ,&nbsp;Yasushi Obase ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.resinv.2025.01.002","DOIUrl":"10.1016/j.resinv.2025.01.002","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 224-225"},"PeriodicalIF":2.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registry","authors":"Masato Kono ,&nbsp;Noriyuki Enomoto ,&nbsp;Yusuke Inoue ,&nbsp;Hideki Yasui ,&nbsp;Masato Karayama ,&nbsp;Yuzo Suzuki ,&nbsp;Hironao Hozumi ,&nbsp;Kazuki Furuhashi ,&nbsp;Mikio Toyoshima ,&nbsp;Shiro Imokawa ,&nbsp;Masato Fujii ,&nbsp;Taisuke Akamatsu ,&nbsp;Naoki Koshimizu ,&nbsp;Koshi Yokomura ,&nbsp;Hiroyuki Matsuda ,&nbsp;Yusuke Kaida ,&nbsp;Yutaro Nakamura ,&nbsp;Masahiro Shirai ,&nbsp;Masafumi Masuda ,&nbsp;Tomoyuki Fujisawa ,&nbsp;Takafumi Suda","doi":"10.1016/j.resinv.2025.01.007","DOIUrl":"10.1016/j.resinv.2025.01.007","url":null,"abstract":"<div><h3>Background</h3><div>Idiopathic interstitial pneumonias (IIPs) may remain unclassifiable owing to inadequate, nonspecific, or conflicting clinical, radiological, or histopathological findings despite multidisciplinary discussion (MDD). Unclassifiable IIP (UCIIP) is a heterogeneous disease that can present with progressive pulmonary fibrosis (PPF). This study aimed to investigate the prevalence and clinical features of PPF in patients with UCIIP.</div></div><div><h3>Methods</h3><div>In this post hoc analysis of a prospective multicenter registry of 222 patients with IIPs, 71 with UCIIP diagnosed using MDD were enrolled. PPF was defined based on worsening symptoms and radiological and physiological progression using the guideline criteria within 12 months or the criteria from the INBUILD trial within 24 months.</div></div><div><h3>Results</h3><div>The median age was 72 years, and surgical lung biopsy was performed in 19.7%. Of the 66 patients with adequate follow-up data, 30 (45.5%) met either criterion and were diagnosed with PPF. UCIIP patients with PPF had significantly higher serum surfactant protein-D level and percentage of bronchoalveolar fluid neutrophils, lower %forced vital capacity and %diffusing capacity for carbon monoxide, and a higher proportion of honeycombing on high-resolution computed tomography and desaturation on exertion than those without PPF. Additionally, they had significantly more anti-fibrotic therapy and long-term oxygen therapy, a higher incidence of acute exacerbation, and a poorer prognosis than those without PPF. Cox proportional hazards analysis revealed that PPF was a significant poor prognostic factor, regardless of the criteria.</div></div><div><h3>Conclusions</h3><div>PPF is common and associated with poor prognosis in patients with UCIIP. Appropriate evaluation and management of PPF are essential for UCIIP.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 216-223"},"PeriodicalIF":2.4,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of poor sleep quality with clinical variables in nontuberculous mycobacterial pulmonary disease","authors":"Yuki Toyoda ,&nbsp;Mitsuru Tabusadani ,&nbsp;Yusuke Matsumura ,&nbsp;Kosuke Mori ,&nbsp;Kazuki Ono ,&nbsp;Kazuma Kawahara ,&nbsp;Shunya Omatsu ,&nbsp;Koji Furuuchi ,&nbsp;Keiji Fujiwara ,&nbsp;Kozo Morimoto ,&nbsp;Hideaki Senjyu ,&nbsp;Ryo Kozu","doi":"10.1016/j.resinv.2025.01.005","DOIUrl":"10.1016/j.resinv.2025.01.005","url":null,"abstract":"<div><h3>Background</h3><div>The high prevalence of poor sleep quality in patients with chronic respiratory diseases makes it an important clinical topic. However, the prevalence and characteristics of poor sleep quality in those with nontuberculous mycobacterial pulmonary disease and its association with clinical variables remain unclear.</div></div><div><h3>Methods</h3><div>This retrospective study involved patients with nontuberculous mycobacterial pulmonary disease between June 2017 and May 2022. The prevalence of poor sleep quality was measured by the Pittsburgh Sleep Quality Index was used to and its association with clinical variables including age, sex, laboratory data, pulmonary function, respiratory symptoms, mental health, health-related quality of life, and physical function was assessed.</div></div><div><h3>Results</h3><div>The median age of 233 participants was 65 years, with poor sleep quality present in 123 patients (52.8%) who were older, female, and unemployed with dyspnea, anxiety symptoms, low health-related quality of life, and low exercise capacity. Many reported that they \"cannot get to sleep within 30 min,\" \"wake up in the middle of the night or early morning,\" \"have to get up to use the bathroom,\" \"cannot breathe comfortably,\" or \"cough or snore loudly.\" Multivariate logistic regression analysis indicated a significant association between poor sleep quality, female sex, and low health-related quality of life.</div></div><div><h3>Conclusion</h3><div>Our results suggested that for the patients in this study, a multidisciplinary management that considers poor sleep quality is required and assessment of sleep quality as a screening is needed.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 210-215"},"PeriodicalIF":2.4,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current drug therapy for pleural mesothelioma","authors":"Hisao Imai","doi":"10.1016/j.resinv.2024.12.017","DOIUrl":"10.1016/j.resinv.2024.12.017","url":null,"abstract":"<div><div>Pleural mesothelioma (PM) is a rare and highly aggressive malignancy originating from the pleural lining, with a median overall survival of merely 1 year. This cancer primarily arises from mesothelial cells following exposure to carcinogenic, biopersistent mineral fibers, particularly asbestos. The histological subtypes of mesothelioma are epithelioid (approximately 60%), sarcomatoid (20%), and biphasic (20%), exhibiting epithelioid and sarcomatoid characteristics. Classification is important for prognosis and guides the therapeutic strategy. Due to the typical late presentation, most patients with PM are ineligible for localized treatments such as surgery or radiotherapy. Systemic therapy, including cytotoxic chemotherapy, targeted therapies, and immunotherapy, is thus critical for managing advanced PM. For unresectable PM, decisions regarding systemic treatment are guided by patient suitability and histological characteristics. First-line therapies for advanced PM currently include the cisplatin–pemetrexed combination and the nivolumab–ipilimumab regimen. Historically, cisplatin–pemetrexed has been administered as first-line treatment, though recent advancements have introduced new therapies that significantly prolong patient survival. Innovative approaches combining immunotherapy and chemotherapy offer promising avenues for further improvement. Future treatment strategies should incorporate novel paradigms, such as combination chemo-immunotherapy, targeted agents, and potential cellular therapies, alongside companion biomarkers tailored to the histologic and molecular diversity of mesothelioma. This review explores the latest advancements in drug therapy for PM and provides an overview of current systemic treatment options.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 200-209"},"PeriodicalIF":2.4,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LPS-induced TMBIM6 splicing drives endothelial necroptosis and aggravates ALI","authors":"Yaling Liu ,&nbsp;Hao Zhu ,&nbsp;Hao Chen ,&nbsp;Yang Gao ,&nbsp;Tingyin Wang ,&nbsp;Xiaodong Wang ,&nbsp;Hong Xie","doi":"10.1016/j.resinv.2024.12.016","DOIUrl":"10.1016/j.resinv.2024.12.016","url":null,"abstract":"<div><h3>Background</h3><div>The mechanism underlying necroptosis in pulmonary vessel endothelial cells (PVECs) resulting from long non-coding RNA (lncRNA)-induced alternative splicing (AS) of target genes in acute lung injury (ALI) remains unclear.</div></div><div><h3>Methods</h3><div>Lipopolysaccharide (LPS)-induced expression of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and lncRNAs was analyzed via RT-PCR in PVECs. Full-transcriptome sequencing was used to detect AS-related mRNAs. The interaction between lncRNA MALAT1 and target gene transmembrane BAX inhibitor motif-containing 6 (TMBIM6) was verified using a dual-luciferase reporter system. Necroptosis was measured as protein levels of phosphorylated receptor-interacting serine/threonine kinase 1 (RIPK1), RIPK3, and mixed-lineage kinase domain-like (MLKL) proteins, as well as flow cytometer measurement. Antisense of MALAT1, TMBIM6, TMBIM6-225 and RIPK1 inhibitor were transfected into a rat model of LPS-induced ALI. Hematoxylin and eosin (H&amp;E) and immunohistochemical staining were performed to evaluate lung injury.</div></div><div><h3>Results</h3><div>LPS upregulated the expression of TNF-α, IL-1β, IL-6, p-RIPK1, p-RIPK3, p-MLKL, MALAT1, and TMBIM6-225 (an AS isoform of MALAT1-targeted gene TMBIM6) in PVECs. However, it downregulated the expression of TMBIM6. An antisense of MALAT1 inhibited TMBIM6-225 and downregulated p-MLKL. The pro-necroptotic effect of MALAT1 was verified in an LPS-induced MALAT1/shMALAT1-transfected ALI rat model <em>in vivo</em>. The necroptotic effect was reversed by treatment with necrostatin-1.</div></div><div><h3>Conclusions</h3><div>LPS-induced MALAT1 causes AS of TMBIM6, and the AS variant TMBIM6-225 aggravates ALI by promoting PVEC necroptosis via the p-RIPK1, p-RIPK3, and p-MLKL complex.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages 191-199"},"PeriodicalIF":2.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors of progression in mild fibrosing interstitial lung disease patients with gender-age-physiology score of 3 or less","authors":"Masaki Okamoto ,&nbsp;Kiminori Fujimoto ,&nbsp;Tomonori Chikasue ,&nbsp;Toyoshi Yanagihara ,&nbsp;Kazuhiro Tabata ,&nbsp;Yoshiaki Zaizen ,&nbsp;Masaki Tominaga ,&nbsp;Akiko Sumi ,&nbsp;Hiroaki Takeoka ,&nbsp;Norikazu Matsuo ,&nbsp;Takashi Nouno ,&nbsp;Atsushi Kawaguchi ,&nbsp;Tomoaki Hoshino","doi":"10.1016/j.resinv.2024.12.005","DOIUrl":"10.1016/j.resinv.2024.12.005","url":null,"abstract":"<div><h3>Background</h3><div>The prognostic factors in mild fibrosing interstitial lung disease (FILD) have not been established.</div></div><div><h3>Methods</h3><div>We retrospectively attempted to identify predictive factors of annual progression in mild FILD with gender-age-physiology (GAP) score of 3 or less using logistic regression analysis. Annual FILD progression was defined as meeting any two or more of the following conditions: 1, more than 10% decrease in forced vital capacity (FVC) or 15% decrease in diffusing capacity of the lungs for carbon monoxide (D_LCO); 2, worsening of dyspnea; 3, worsening of fibrotic change on CT at 1 year after admission.</div></div><div><h3>Results</h3><div>Univariate analysis showed that diagnosis of connective tissue disease-associated ILD, CT-definite usual interstitial pneumonia (UIP) pattern, composite physiologic index, FVC, D_LCO, lowest SpO₂ and decrease in SpO₂, and walk distance in the 6-minutes walk test (6MWT), chronic pulmonary emphysema assessment test (CAT) score, and some variables in Short-Form 36 were significantly associated with incidence of annual progression. Multivariate analysis showed that independent predictive factors were diagnosis of idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (HP), CT-definite UIP pattern, lowest SpO₂ and decrease in SpO₂ in the 6MWT, and CAT score. In logistic regression analysis among 63 patients with non-IPF-ILD, diagnosis with fibrotic HP, lowest SpO₂ and decrease in SpO₂ in the 6MWT, and CAT score were also independent risk factors for annual FILD progression.</div></div><div><h3>Conclusions</h3><div>Exercise-induced hypoxia, patient-reported outcome, radiological UIP pattern, and diagnosis with fibrotic HP are independent predictors of annual progression in mild FILD.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 109-117"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor, in chronic obstructive pulmonary disease: A systematic review and meta-analysis","authors":"Eeshal Fatima ,&nbsp;Obaid Ur Rehman ,&nbsp;Zain Ali Nadeem ,&nbsp;Umar Akram ,&nbsp;Riyan Imtiaz Karamat ,&nbsp;Muhammad Omar Larik ,&nbsp;Maurish Fatima ,&nbsp;Joshua Chitwood ,&nbsp;Arslan Ahmad ,&nbsp;Sarah Esposito ,&nbsp;Abdulqadir J. Nashwan","doi":"10.1016/j.resinv.2024.12.012","DOIUrl":"10.1016/j.resinv.2024.12.012","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated the efficacy and safety of Ensifentrine in COPD via a systematic review and meta-analysis of randomized controlled trials (RCTs).</div></div><div><h3>Methods</h3><div>We performed a detailed literature search on Medline (via PubMed), Scopus, Google Scholar, and Cochrane on the basis of pre-specified eligibility criteria. We used Review Manager to calculate pooled mean differences (MD) and 95% Confidence Interval (CI) using a random effects model. The Cochrane's Risk of Bias 2 (RoB-2) tool was used to assess the risk of bias in the included RCTs.</div></div><div><h3>Results</h3><div>A total of 4 studies, consisting of 2020 patients, were included in the meta-analysis. The mean age ranged from 62.5 years to 65.5 years in the included studies. All the included studies were at low risk of bias. Ensifentrine 3 mg dose significantly improved the mean peak Forced Expiratory Volume-1 (FEV-1), morning trough FEV-1, TDI score, ERS score, and SGRQ-C score as compared to the placebo, yielding a pooled MD of 149.76 (95% CI, 127.9 to 171.6), 43.93 (95% CI, 23.82 to 64.05), 0.92 (95% CI, 0.64 to 1.21, −1.20 (95% CI, −1.99 to −0.40), and −1.92 (95% CI, −3.24 to −0.59), respectively.</div></div><div><h3>Conclusion</h3><div>Ensifentrine is associated with improvements in outcomes related to COPD symptoms such as peak FEV-1, morning trough FEV-1 and TDI in the patients suffering from this chronic disease. It is also associated with improved quality of life as seen by E-RS score and SGRQ-C score.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 146-155"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and causes of subacute cough in Japan","authors":"Yoshihisa Ishiura ,&nbsp;Masaki Fujimura ,&nbsp;Haruhiko Ogawa ,&nbsp;Johsuke Hara ,&nbsp;Hiromoto Shintani ,&nbsp;Soichiro Hozawa ,&nbsp;Ryo Atsuta ,&nbsp;Kensuke Fukumitsu ,&nbsp;Hideki Inoue ,&nbsp;Takanobu Shioya ,&nbsp;Masato Muraki ,&nbsp;Tokunao Amemiya ,&nbsp;Noriyuki Ohkura ,&nbsp;Yoshitaka Oribe ,&nbsp;Hiroshi Tanaka ,&nbsp;Takechiyo Yamada ,&nbsp;Mikio Toyoshima ,&nbsp;Katsuya Fujimori ,&nbsp;Tamotsu Ishizuka ,&nbsp;Manabu Kagaya ,&nbsp;Akio Niimi","doi":"10.1016/j.resinv.2024.11.007","DOIUrl":"10.1016/j.resinv.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>Subacute cough is subdivided and distinguished from chronic cough, because post-infectious cough is considered to be the main cause of subacute cough and differs from acute and chronic cough. However, the details of the spectrum and frequency of causes of subacute cough remain unclear because only two studies on subacute cough have been published.</div></div><div><h3>Methods</h3><div>Patients who presented with cough that lasted for 3–8 weeks and visited respiratory clinics or hospitals affiliated with the Japan Cough Society during 2 years were studied.</div></div><div><h3>Results</h3><div>A total of 148 patients were prospectively enrolled, and those who did not meet the definition of subacute cough were excluded. Ninety-seven (68.3%) patients with subacute cough progressed to chronic cough, and the main causative diseases were cough variant asthma in 44 patients, atopic cough in 24 patients, sinobronchial syndrome in 13 patients, and post-infectious cough in seven patients. Patients with cough variant asthma complicated by atopic cough and those in whom the cause of subacute cough was unknown tended to develop chronic cough.</div></div><div><h3>Conclusions</h3><div>This study shows that post-infectious cough is less common than previously thought and the main causes of subacute cough are cough variant asthma, atopic cough, and sinobronchial syndrome and their complications. Cough variant asthma in combination with atopic cough also can be a precursor of refractory chronic cough. The careful diagnosis and treatment of two or more causative diseases is required in patients with subacute cough.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 74-80"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study","authors":"Shinji Abe ,&nbsp;Arata Azuma ,&nbsp;Yoshinobu Saito ,&nbsp;Hiroki Hayashi ,&nbsp;Takeru Kashiwada ,&nbsp;Toru Tanaka ,&nbsp;Tomohisa Baba ,&nbsp;Akimasa Sekine ,&nbsp;Hideya Kitamura ,&nbsp;Ryo Okuda ,&nbsp;Satoshi Ikeda ,&nbsp;Takashi Ogura","doi":"10.1016/j.resinv.2024.11.017","DOIUrl":"10.1016/j.resinv.2024.11.017","url":null,"abstract":"<div><h3>Background</h3><div>The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is extremely poor. However, recent clinical reports suggest that direct hemoperfusion with polymyxin B-immobilized fiber column (PMX) treatment may have beneficial effects in patients with AE-IPF. The aim of this multicenter prospective study was to investigate the effectiveness and safety of PMX treatment in AE-IPF.</div></div><div><h3>Methods</h3><div>We conducted a prospective study of patients with AE-IPF treated by PMX at two institutions in Japan. Each patient received 2–3 sessions of PMX treatment with a target duration of 6–24 h. The primary endpoint was the survival rate at day 28 after the PMX treatment.</div></div><div><h3>Results</h3><div>The survival rate of the patients on day 28 after PMX treatment was 65% [95% confidence interval (CI): 40.3–81.5%]. The lower limit of 95% CI in the study was higher than the survival rate of 40%, which was the upper limit of the survival rate in AE-IPF receiving conventional treatments, as reported previously. The survival rate of the patients 12 weeks after PMX was 50% (95% CI: 27.1–69.2%). The changes in the difference between alveolar and arterial oxygen tension and the partial pressure of arterial oxygen/fraction of inspired oxygen improved as the number of PMX sessions increased, and significant improvements were observed at the end of the second PMX session. The safety of PMX was clinically acceptable.</div></div><div><h3>Conclusions</h3><div>This prospective multicenter study suggests that PMX treatment is safe for patients with AE-IPF and may improve their oxygenation and prognosis.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 1","pages":"Pages 102-108"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}